

---

## TABLE OF CONTENTS

<b>FOUNDATION OF PEDIATRIC PHARMACY PRACTICE: PRINCIPLES, COMMUNICATIONS, AND EDUCATION. . . . .</b>	<b>1</b>
<i>Principles of Pediatrics; Communications with Pediatric Patients and Caregivers; Education for Pharmacy Students, Postgraduate Trainees, and Pharmacists</i>	
<b>BIOSTATISTICS . . . . .</b>	<b>57</b>
<i>Biostatistics: An Important Practice Tool; Types of Variables/Data; Types of Statistics; Population Distributions; Confidence Intervals; Hypothesis Testing; Decision Errors When Comparing Groups; Choosing a Statistical Test When Comparing Groups; Correlation and Regression; Survival Analysis; Selected Representative Statistical Tests</i>	
<b>STUDY DESIGNS . . . . .</b>	<b>83</b>
<i>Introduction; Various Issues in Study Design; Case Reports/Case Series; Observational Study Designs; Incidence, Prevalence, Relative Risk/Risk Ratios, and Odds Ratios; Randomized Controlled Trial Design; Other Issues to Consider in Randomized Controlled Trials; Randomized Controlled Clinical Trials: Analysis; Common Approaches to Analyzing Clinical Trials; Systematic Review/Meta-Analysis; Summary Measures of Effect; Reporting Guidelines for Clinical Studies; Pharmacoeconomic Studies; Sensitivity/Specificity/Predictive Values; Institutional Review Board (IRB) and Human Subjects' Research</i>	
<b>MEDICATION SAFETY . . . . .</b>	<b>117</b>
<i>Introduction; Definitions; Pediatric Medication Error Incidence; Pediatric-Specific Risk Factors for Medication Errors and Harm; Strategies for Error and Harm Detection, Measurement, and Improvement Methods; Error and Risk Mitigation Considerations and Strategies; Error and Risk Mitigation Strategies</i>	
<b>PICU I . . . . .</b>	<b>151</b>
<i>Shock; Sedation/Analgesia/Neuromuscular Blockade/Intensive Care Unit Delirium; Extracorporeal Membrane Oxygenation; Cardiac Arrest; Traumatic Brain Injury; Burns</i>	
<b>PICU II . . . . .</b>	<b>187</b>
<i>Acid-Base Disorders; Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State; Status Epilepticus; Acute Respiratory Distress Syndrome; Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia; Stress-Related Mucosal Disease and Upper Gastrointestinal Bleeding</i>	
<b>NEONATOLOGY. . . . .</b>	<b>233</b>
<i>Respiratory Distress Syndrome; Bronchopulmonary Dysplasia; Apnea of Prematurity; Intraventricular Hemorrhage; Patent Ductus Arteriosus; Necrotizing Enterocolitis; Persistent Pulmonary Hypertension of the Newborn; Congenitally Acquired Infections; Neonatal Abstinence Syndrome; Drugs in Pregnancy and Lactation</i>	
<b>ENDOCRINE DISORDERS . . . . .</b>	<b>285</b>
<i>Diabetes Mellitus; Obesity; Hyperthyroidism; Hypothyroidism; Syndrome of Inappropriate Antidiuretic Hormone; Adrenal Insufficiency; Diabetes Insipidus</i>	
<b>PHARMACOKINETICS, PHARMACODYNAMICS, PHARMACOGENOMICS AND DRUG FORMULATIONS . . . . .</b>	<b>321</b>
<i>Introduction; Pharmacokinetics; Pharmacodynamics; Pharmacogenomics; Compounded Drug Formulations for the Pediatric Population</i>	

---

<b>PRACTICE MANAGEMENT</b> . . . . .	<b>359</b>
<i>Introduction; Pediatric Considerations for Maintaining a Formulary and Developing Medication Use Guidelines or Protocols; Providing Pediatric Pharmacy Services in Hospitals and Health Systems; Improving the Quality of Medication Management Services Provided to Pediatric Patients</i>	
<b>TOXICOLOGY</b> . . . . .	<b>399</b>
<i>Poison Control Center Overview; Legislative Changes; Pediatric Poisonings; General Toxicology; Management of Select Agents; Select Antidotes; Substance Use Disorders</i>	
<b>GASTROENTEROLOGY</b> . . . . .	<b>441</b>
<i>Gastroesophageal Reflux Disease; Diarrhea; Constipation; Irritable Bowel Syndrome; Inflammatory Bowel Disease; Short Bowel Syndrome; Appendicitis; Nausea and Vomiting; Ulcers</i>	
<b>INFECTIOUS DISEASES</b> . . . . .	<b>523</b>
<i>Lower Respiratory Tract Infections; Upper Respiratory Tract Infections; Acute Otitis Media; Skin and Soft Tissue Infections; Bone and Joint Infections; Central Nervous System Infections; Urinary Tract Infections; Catheter-Related Bloodstream Infections; Endocarditis; Intra-abdominal Infections; Fungal Infections; Parasitic Infections; Sepsis/Septic Shock; Tuberculosis; Sexually Transmitted Diseases; Surgical Prophylaxis</i>	
<b>HEMATOLOGY/ONCOLOGY</b> . . . . .	<b>583</b>
<i>Introduction; Supportive Care in Pediatric Oncology; Introduction to Pediatric Oncology; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Non-Hodgkin Lymphomas; Hodgkin Lymphoma; Central Nervous System Tumors; Neuroblastoma; Wilms Tumor; Osteosarcoma; Ewing Tumors and Ewing Sarcoma; Rhabdomyosarcoma; Retinoblastoma; Hematopoietic Stem Cell Transplantation; Sickle Cell Disease; Iron Deficiency Anemia; Hemophilias</i>	
<b>SOLID ORGAN TRANSPLANTATION</b> . . . . .	<b>641</b>
<i>History; Organs Transplanted and Survival Rates; Survival; Indications for Solid Organ Transplantation; Pretransplant Evaluation; Surgical Solid Organ Transplantation Procedure; T-Cell Signaling and Replication; Immunobiology of Solid Organ Transplant Rejection; Types of Rejection; Immunosuppressive Therapy; Corticosteroids; Calcineurin Inhibitors Used for Solid Organ Transplantation; Antiproliferative Agents; Mammalian Target of Rapamycin Inhibitors; Lymphocyte-Depleting Agents; Interleukin-2 Receptor Antagonists; Other Biologic and Novel Agents in Solid Organ Transplantation; Anti-Infection; Other Considerations After Transplantation</i>	
<b>CARDIOLOGY</b> . . . . .	<b>695</b>
<i>Kawasaki Disease; Congenital Heart Diseases; Pediatric Hypertension; Arrhythmias; Anticoagulation; Pulmonary Hypertension</i>	
<b>PULMONARY</b> . . . . .	<b>769</b>
<i>Asthma; Status Asthmaticus; Cystic Fibrosis; Community-Acquired Pneumonia</i>	

---

**PEDIATRIC PUBLIC HEALTH . . . . . 815**  
*Advocacy for the Pediatric Patient Population in Health Care Policy; Importance of Age-Appropriate Dosage Forms, Product Labeling, and Pediatric Population–Specific Considerations; Medication Error Prevention in the Pediatric Patient Through Automation and Technology; Managing Drug Shortages, Advocating for Drug Allocation to the Pediatric Patient, and Considerations Unique to the Pediatric Patient Population; Pediatric Advocacy Through Professional Organizations, Federal Agencies, and Accrediting Bodies; Importance and Value of Postdoctoral Pediatric-Trained Pharmacy Specialists and Pediatric Clinical Specialists; Drug Warnings and Information Involving the Pediatric Population; Complementary and Alternative Medicine; Childhood Poisoning; Vaccines; Secondhand Smoke and Tobacco Exposure; Bioterrorism; Challenges of Pediatric Pharmacy Practice*

**IMMUNOLOGY. . . . . 853**  
*Eczema/Atopic Dermatitis; Juvenile Idiopathic Arthritis; Severe Combined Immunodeficiency; Vaccinations; Anaphylaxis; Food Allergies; Acute Rheumatic Fever and Rheumatic Heart Disease; Systemic Lupus Erythematosus; Human Immunodeficiency Virus*

**NEPHROLOGY . . . . . 927**  
*Nephrotic Syndrome; Comorbidities in Pediatric Nephrotic Syndrome; Hydronephrosis; Renal Tubular Acidosis; Acute Kidney Injury (Acute Renal Failure); Chronic Kidney Disease; Renal Replacement Therapy; Hemolytic Uremic Syndrome; Tubulointerstitial Nephritis*

**NEUROLOGY/PSYCHIATRY. . . . . .1001**  
*Migraines/Headaches; Seizure Disorders (Chronic Management); Cerebral Palsy; Autism Spectrum Disorders; Pediatric Bipolar Disorder; Attention-Deficit/Hyperactivity Disorder; Pediatric Depression*

**FLUIDS, ELECTROLYTES, AND NUTRITION . . . . . .1051**  
*Composition of Body Fluids; Types of Intravenous Fluid; Maintenance Fluids and Electrolytes; Dehydration; Sodium Homeostasis; Nutrition Assessment; Caloric Requirements; Enteral Nutrition; Parenteral Nutrition: Delivery of Nutrition Directly into the Bloodstream Through Venous Access Devices; Safety Considerations/Complications of Parenteral Nutrition; Failure to Thrive*